Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 7838 results found since Jan 2013.

Thrombotic thrombocytopenic purpura in a case of dengue fever: A rare presentation
Abhijit S Gavali, Jayant Shelgaonkar, Sandip BartakkeIndian Journal of Critical Care Medicine 2017 21(4):226-228Here, we present an unusual occurrence of thrombotic thrombocytopenic purpura (TTP) in a case of dengue fever. Both the conditions are fatal and can result in significant mortality and morbidity if left untreated. In this case, as soon as, we diagnosed the patient as having TTP, we treated her with plasma exchange therapy, steroids, and monoclonal antibodies such as rituximab. The patient responded very well to the treatment and completely recovered from neurological symptoms and laboratory parameters also normal...
Source: Indian Journal of Critical Care Medicine - April 11, 2017 Category: Intensive Care Authors: Abhijit S Gavali Jayant Shelgaonkar Sandip Bartakke Source Type: research

International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis.
rrier B, Tzioufas AG, Vaglio A, Zhao MH, Cohen Tervaert JW, European EGPA Study Group Abstract An international consensus on anti-neutrophil cytoplasm antibodies (ANCA) testing in eosinophilic granulomatosis with polyangiitis (EGPA) is presented. ANCA, specific for myeloperoxidase (MPO), can be detected in 30-35% of EGPA patients. MPO-ANCA should be tested with antigen-specific immunoassays in any patient with eosinophilic asthma and clinical features suggesting EGPA, including constitutional symptoms, purpura, polyneuropathy, unexplained heart, gastrointestinal or kidney disease, and/or pulmonary infiltrates or h...
Source: American Journal of Respiratory and Critical Care Medicine - June 24, 2020 Category: Respiratory Medicine Authors: Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, Emmi G, Flores-Suárez LF, Hellmich B, Jayne D, Jennette JC, Little MA, Mohammad AJ, Moosig F, Novikov P, Pagnoux C, Radice A, Sada KE, Segelmark M, Shoenfeld Y, Sinico RA, Specks U, T Tags: Am J Respir Crit Care Med Source Type: research

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial
CONCLUSIONS: B cell depletion therapy is a potentially effective and safe adjuvant treatment for SSc-PAH. Future studies in these patients can confirm whether the identified biomarkers predict rituximab-responsiveness. Clinical trial registration available at www.clinicaltrials.gov, ID: NCT01086540.PMID:33651671 | DOI:10.1164/rccm.202009-3481OC
Source: American Journal of Respiratory and Critical Care Medicine - March 2, 2021 Category: Respiratory Medicine Authors: Roham T Zamanian David Badesch Lorinda Chung Robyn T Domsic Thomas Medsger Ashley Pinckney Lynette Keyes-Elstein Carla D'Aveta Meagan Spychala R James White Paul M Hassoun Fernando Torres Andrew J Sweatt Jerry A Molitor Dinesh Khanna Holden Maecker Beverl Source Type: research

A Phase-2 NIH-Sponsored Randomized Clinical Trial of Rituximab in SSC-PAH Did Not Reach Significance for its Endpoints: End of Story? Not so Fast!
Am J Respir Crit Care Med. 2021 Apr 15. doi: 10.1164/rccm.202103-0612ED. Online ahead of print.NO ABSTRACTPMID:33856964 | DOI:10.1164/rccm.202103-0612ED
Source: American Journal of Respiratory and Critical Care Medicine - April 15, 2021 Category: Respiratory Medicine Authors: Yongneng Zhang Evangelos D Michelakis Source Type: research

Treatment of Pulmonary Vasculitis
Semin Respir Crit Care Med 2018; 39: 504-510 DOI: 10.1055/s-0038-1669414Pulmonary vasculitis can be heterogeneous and have some pathophysiological, clinical, and biological specificities that might influence treatment choices. Main vasculitides associated with pulmonary vasculitis include antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, immune complex small vessel vasculitis, and antiglomerular basement membrane disease. Patient characteristics and association of lung involvement with other manifestations affecting disease severity may also influence treatment strategy. Alveolar hemorrhage frequently req...
Source: Seminars in Respiratory and Critical Care Medicine - November 7, 2018 Category: Respiratory Medicine Authors: Terrier, Benjamin Guillevin, Lo ïc Tags: Review Article Source Type: research

Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment
Semin Respir Crit Care Med 2018; 39: 434-458 DOI: 10.1055/s-0038-1660874Granulomatosis with polyangiitis (GPA), formerly termed Wegener's granulomatosis, is the most common of the pulmonary vasculitides. GPA typically involves the upper respiratory tract, lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. Cardinal histologic features include a necrotizing vasculitis involving small vessels, extensive “geographic” necrosis, and granulomatous inflammation. The spectrum and severity of the disease is heterogeneous, ranging from indolent disease involving only one site ...
Source: Seminars in Respiratory and Critical Care Medicine - November 7, 2018 Category: Respiratory Medicine Authors: Lynch, Joseph P. Derhovanessian, Ariis Tazelaar, Henry Belperio, John A. Tags: Review Article Source Type: research

Alveolar Hemorrhage in Vasculitis (Primary and Secondary)
Semin Respir Crit Care Med 2018; 39: 482-493 DOI: 10.1055/s-0038-1668533Defined by the accumulation of red blood cells into the alveolar space, diffuse alveolar hemorrhage (DAH) is a severe and potentially fatal medical condition requiring careful attention. In contrast to simple extravasation of erythrocytes facilitated by impaired hemostasis or hemodynamic causes, DAH in vasculitis is due to capillaritis, that is, inflammation of capillaries. Dyspnea, hemoptysis, chest infiltrates, and abrupt fall of blood hemoglobin level represent the cardinal features of DAH; yet, hemoptysis is lacking in one-third of cases. Bronchoal...
Source: Seminars in Respiratory and Critical Care Medicine - November 7, 2018 Category: Respiratory Medicine Authors: Nasser, Mouhamad Cottin, Vincent Tags: Review Article Source Type: research

Lung Diseases in Inflammatory Myopathies
Semin Respir Crit Care Med 2019; 40: 255-270 DOI: 10.1055/s-0039-1685187Lung involvement is the leading cause of mortality in inflammatory myopathy. A careful assessment of clinical and serologic manifestations especially myositis-associated autoantibodies allows precise classification of the different phenotypes of inflammatory myopathy and stratification of the risk of lung involvement. About three out of four patients with inflammatory myopathy develop interstitial lung disease (ILD), which represents the main cause of morbidity and mortality. In patients with a confirmed diagnosis of inflammatory myopathy, the approach...
Source: Seminars in Respiratory and Critical Care Medicine - May 27, 2019 Category: Respiratory Medicine Authors: Barba, Thomas Mainbourg, Sabine Nasser, Mouhamad Lega, Jean-Christophe Cottin, Vincent Tags: Review Article Source Type: research

Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research

Diagnosis and treatment of neoplastic post-transplant lymphoproliferative disorder following hematopoietic stem cell transplant in β-thalassemia: A pediatric case report
Conclusion:The current case represents a unique opportunity to review a pediatric patient with β-thalassemia. The successful treatment of post-transplant non-Hodgkin B lymphoma may help other physicians in the management of similar pediatric cases. Introduction: Post-transplant lymphoproliferative disorder (PTLD) is the most common form of lymphoproliferation in childhood and is associated with significant morbidity and mortality. In this report we reviewed the case of a pediatric patient who experienced PTLD after allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA)-identical...
Source: Medicine - December 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Clinical diagnosis and treatment of pediatric anti-N-methyl-D-aspartate receptor encephalitis: A single center retrospective study.
Authors: Sai Y, Zhang X, Feng M, Tang J, Liao H, Tan L Abstract The aim of the present retrospective study was to investigate the diagnosis, treatment and prognosis of pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. A total of 23 pediatric patients with anti-NMDAR encephalitis were included in the present study. The clinical data, laboratory test results, imaging examination, treatment outcomes, and follow-up records were reviewed and analyzed. A total of 8 patients exhibited prodromal symptoms, including fever, cough, and vomiting. Clinical symptoms included epilepsy, convulsions, ataxia, c...
Source: Experimental and Therapeutic Medicine - August 18, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union
AbstractRegulatory agencies of the USA and European Union (EU) have introduced multiple guidelines in the last decade to standardize and accelerate biosimilar development. As a result, a large number of biosimilars are being approved in the USA and EU. In the present review, we identified the biosimilars and their corresponding reference biologics approved for pediatrics in the USA and EU, and then assessed their approval details. In the USA, a biosimilar applicant needs to submit an initial pediatric study plan under the Pediatric Research Equity Act (PREA). We found that the PREA requirements of a pediatric assessment fo...
Source: Pharmaceutical Medicine - February 17, 2021 Category: Drugs & Pharmacology Source Type: research

Successful treatment of severe lactic acidosis and tumor lysis syndrome related to intravascular lymphoma in the intensive care unit.
We report a rare case in which a patient with intravascular lymphoma involving multiple organ failure survived. PMID: 31308316 [PubMed - as supplied by publisher]
Source: Journal of Nippon Medical School - July 14, 2019 Category: Universities & Medical Training Authors: Mase H, Ogawa Y, Takeuchi J, Genda Y, Ichiba S, Sakamoto A Tags: J Nippon Med Sch Source Type: research